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Abstract
Background: CTLA4-blocking antibodies induce tumor regression in a subset of patients with
melanoma. Analysis of immune parameters in peripheral blood may help define how responses are
mediated.
Methods:  Peripheral blood from HLA-A*0201-positive patients with advanced melanoma
receiving tremelimumab (formerly CP-675,206) at 10 mg/kg monthly was repeatedly sampled
during the first 4 cycles. Samples were analyzed by 1) tetramer and ELISPOT assays for reactivity
to CMV, EBV, MART1, gp100, and tyrosinase; 2) activation HLA-DR and memory CD45RO
markers on CD4+/CD8+ cells; and 3) real-time quantitative PCR of mRNA for FoxP3 transcription
factor, preferentially expressed by T regulatory cells. The primary endpoint was difference in
MART1-specific T cells by tetramer assay. Immunological data were explored for significant trends
using clustering analysis.
Results: Three of 12 patients eligible for immune monitoring had tumor regression lasting > 2
years without relapse. There was no significant change in percent of MART1-specific T cells by
tetramer assay. Additionally, there was no generalized trend toward postdosing changes in other
antigen-specific CD8+ cell populations, FoxP3 transcripts, or overall changes in surface expression
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of T-cell activation or memory markers. Unsupervised hierarchical clustering based on immune
monitoring data segregated patients randomly. However, clustering according to T-cell activation
or memory markers separated patients with clinical response and most patients with inflammatory
toxicity into a common subgroup.
Conclusion:  Administration of CTLA4-blocking antibody tremelimumab to patients with
advanced melanoma results in a subset of patients with long-lived tumor responses. T-cell
activation and memory markers served as the only readout of the pharmacodynamic effects of this
antibody in peripheral blood.
Clinical trial registration number: NCT00086489
Background
Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) is
an activation-induced, type I transmembrane protein of
the immunoglobulin superfamily, expressed by recently
activated T lymphocytes as a covalent homodimer. It func-
tions as an inhibitory receptor for the costimulatory mol-
ecules B7.1 (CD80) and B7.2 (CD86), efficiently
competing with the positive costimulatory receptor CD28
[1-5]. Crosslinking of CTLA4 by B7 in the context of T-cell
antigen receptor (TCR) engagement inhibits T-cell activa-
tion, interleukin (IL)-2 gene transcription, and T-cell pro-
liferation by directly inhibiting TCR signal transduction
[3,6].
CTLA4 blockade using the specific antagonistic mono-
clonal antibodies ipilimumab (formerly known as
MDX010 and BMS734016) and tremelimumab (formerly
known as CP-675,206 and ticilimumab) reproducibly
induce objective tumor responses in a subset of patients
with melanoma [7-15]. Despite a wealth of knowledge
about the antitumor activity induced by CTLA4 blockade
in animal models, the mechanisms that mediate tumor
regression in human patients are currently not fully
understood [16,17]. Several mechanisms have been pos-
tulated: 1) Blocking the negative signaling from CTLA4
expressed on recently activated tumor antigen-specific T
cells may boost natural or induced immune responses to
cancer cells [3,18]; 2) Anti-CTLA4 antibodies may deplete
CD4+CD25+ T regulatory cells (Treg) [19], which constitu-
tively express CTLA4 [20], or inhibit reverse signaling to
B7 costimulatory molecules expressed by immune sup-
pressive plasmacytoid dendritic cells (pDC) [21-23] or
activated T cells [24]; 3) Anti-CTLA4 antibodies may result
in the presence of high titers of antibodies against soluble
major histocompatibility complex (MHC) class I chain-
related protein A (MICA), an immune suppressive MHC
class I-like molecule shed by tumor cells [25]; 4) Expres-
sion of CTLA4 on T cells increases their motility and inter-
feres with establishment of durable interactions with cells
expressing their cognate antigen [26], which may be
reverted with monoclonal antibodies; or 5) Anti-CTLA4
antibodies may have direct cytotoxic effects on tumor cells
that express CTLA4 [27].
Some of these hypotheses can be studied using modern
immune monitoring assays in peripheral blood. Quantifi-
cation of antigen-specific T-cell responses by MHC
tetramer and enzyme-linked immunospot (ELISPOT)
assays is often used to assess immune activation in exper-
imental cancer immunotherapy trials [28]. Definition of
key methodological parameters (ie, accuracy, precision,
and reproducibility) is critical to determine the extent of
T-cell expansion that represents a positive immune
response. The magnitude of minimum statistically signif-
icant changes in the number of circulating antigen-specific
T cells compared with baseline levels (defined as the refer-
ence change value [RCV]) was recently reported for the
tetramer and ELISPOT assays [29]. This calculation pro-
vides a robust definition of immune response (either pos-
itive or negative) that can be reliably applied to the
monitoring of immunomodulatory effects of CTLA4-
blocking monoclonal antibodies.
Tremelimumab is a fully human immunoglobulin (Ig)G2
monoclonal antibody with high CTLA4 specificity that
antagonizes binding of CTLA4 to B7 costimulatory mole-
cules, resulting in enhanced T-cell activation as demon-
strated by increased cytokine production in vitro.
Tremelimumab has demonstrated antitumor activity in
patients with metastatic melanoma [12]. As with any
study using patient-derived samples, the ability to
robustly test or rule out a hypothesis is limited by practical
constraints of human experimentation [30]. Within these
limitations, we set up to test the hypothesis that tremeli-
mumab may alter the number, functional activation or
phenotype of immune cells in peripheral blood that may
provide information on the mechanism of action of this
CTLA4-blocking monoclonal antibody. Therefore, in this
report we analyzed immune parameters in the peripheral
blood of patients receiving tremelimumab for the treat-
ment of locally advanced or metastatic melanoma with
the goal of studying the mechanism of immune activation
leading to objective tumor responses.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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Materials and methods
Study Design and Assessments
Human leukocyte antigen (HLA)-A*0201-positive
patients with metastatic melanoma who received tremeli-
mumab monthly at the maximum tolerated dose in a
phase I trial [31] were enrolled in an open-label expan-
sion cohort between June 2004 and April 2005, and con-
sented to donate repeated peripheral blood samples while
receiving tremelimumab (10 mg/kg monthly) intrave-
nously for up to 24 cycles. This study was conducted
according to the Declaration of Helsinki and its amend-
ments and relevant International Conference on Harmo-
nization Good Clinical Practice guidelines. The protocol
and consent forms, and all modifications, were approved
by the University of California Los Angeles and University
of Texas MD Anderson institutional review boards
(approval numbers 03-01-059 and IDO3-0090, respec-
tively). All patients provided written informed consent
prior to any study procedures. Blood samples (40 mL)
were collected from a peripheral vein during the screening
period, on day 1 before the first dose of antibody (both
baseline samples), on the day of each new dose in subse-
quent cycles, and 1 and 2 weeks after each monthly dose
during the first 4 monthly cycles of therapy. When possi-
ble, a final blood sample was collected at the time the
patient went off study for whatever reason. All patients
underwent baseline and follow-up eye exams every 2 to 4
months throughout study participation following our pre-
viously-published eye surveillance protocol [32,33]. The
primary endpoint was the determination of immune
response to the melanoma-associated antigen recognized
by T cells (MART1)-derived epitope MART126–36 by MHC
tetramer assay across multiple time points. This was
defined as detecting a 99% RCV for this assay and antigen,
which corresponds to a minimum 80% change from base-
line in the percentage of circulating antigen-specific T cells
[29]. Clinical responses were assessed by Response Evalu-
ation Criteria in Solid Tumors (RECIST) [34]. In addition,
a clinical benefit response was defined for patients who
were felt by the study investigators to have derived une-
quivocal clinical benefit after tremelimumab despite not
meeting the standard criteria for response following
RECIST.
Patient Eligibility
Patients with surgically incurable stage IIIc or IV
melanoma were eligible if they met the following major
eligibility criteria: HLA-A*0201 positive, baseline level of
circulating MART126–36-specific T cells above the lower
limit of detection (LLD) by tetramer assay, previously
defined as 0.03% of CD8+ T cells [29], disease measurable
by RECIST, Eastern Cooperative Oncology Group per-
formance status ≤ 1, and having received at least 2 doses
of tremelimumab with samples for immune monitoring
collected weekly between both doses. Major exclusion cri-
teria were history of chronic inflammatory or autoim-
mune disease and presence of active brain metastases.
Sample Processing, Cryopreservation, and Thawing
Peripheral blood mononuclear cells (PBMC) were iso-
lated by Ficoll-Hypaque (Amersham Pharmacia, Piscata-
way, NJ) and cryopreserved in liquid nitrogen in Roswell
Park Memorial Institute medium (RPMI) (Gibco-BRL,
Gaithersburg, MD) supplemented with 20% (all percent-
ages represent v/v) heat-inactivated human AB serum
(Omega Scientific, Tarzana, CA) and 10% dimethylsulfox-
ide (Sigma, St. Louis, MO). Cryopreserved PBMC aliquots
were thawed and immediately diluted with RPMI com-
plete media consisting of 10% human AB serum and 1%
penicillin, streptomycin, and amphotericin (Omega Sci-
entific). Cells were washed and subjected to enzymatic
treatment with DNAse (0.002%, Sigma) for 1 hour at
37°C. Cells were washed again and used immediately or
were rested overnight in RPMI complete media in a 6%
CO2 incubator.
MHC Tetramer Assay
The following peptide epitopes were used: 1) 2 negative
control epitopes: an HLA-A*0201-binding nonrelevant
peptide (referred to as Negative peptide from here on)
[35], and the HLA-A*0201 immunodominant peptide
alpha fetoprotein (AFP)325–332  (GLSPNLNRFL) derived
from the oncofetal antigen AFP [36]; 2) 2 infectious dis-
ease epitopes as positive controls, cytomegalovirus
(CMV)pp65495–503 (NLVPMVATV) and Epstein-Barr virus
(EBV) BMLF1259–267  (GLCTLVAML); and 3) 3 HLA-
A*0201 immunodominant peptides derived from tumor
rejection antigens: MART126–35  (ELAGIGILTV),
tyrosinase368–376  (YMDGTMSQV) and gp100209–217
(ITDQVPFSV). All HLA-A*0201 tetramers were purchased
from Beckman Coulter Inc., San Diego, CA, as peptide
preloaded reagents, and the assay was performed follow-
ing the manufacturer's instructions with minor modifica-
tions as previously described [29].
ELISPOT Assays
Interferon gamma (IFN-γ) ELISPOT assays were also per-
formed as previously described [29]. Briefly, PBMC were
thawed from different time points and treated with
DNAse. HLA-A*0201-transfected K562 (K562/A*0201),
provided by Drs. Wolfgang Herr and Cedrik M. Britten
(Johannes Gutenberg University, Mainz, Germany), were
pulsed with the same peptide epitopes described for the
tetramer assay and used as antigen-presenting cells. Then
1 × 105 PBMC were mixed with 1 × 104 peptide-pulsed
K562/A*0201 in X-Vivo 10 media (BioWhittaker, Walk-
ersville, MD) supplemented with 10% heat-inactivated
human AB serum and seeded directly into anti-IFN-γ anti-
body coated ELISPOT plates for 20 hours.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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Multiplex Cytokine Assay
Cocultures of thawed PBMC and peptide pulsed K562/
A*0201 cells were plated as described for ELISPOT assays
but were placed in triplicate in flat-bottom 96-well plates.
Twenty hours later, supernatants were collected and fro-
zen after centrifugation at 468 g for 10 minutes. Thawed
supernatants from different time points were analyzed fol-
lowing the manufacturer's instructions using a 17-plex
assay (Bio-Plex Human Cytokine 17-Plex Panel, Bio-Rad
Laboratories, Hercules, CA). The cytokines quantified
were IL-2, IL-4, IL-6, IL-8, IL-10, granulocyte-macrophage
colony-stimulating factor (GM-CSF), IFN-γ, tumor necro-
sis factor alpha (TNF-α), IL-1β, IL-5, IL-7, IL-12 (p70), IL-
13, IL-17, granulocyte colony-stimulating factor (G-CSF),
monocyte chemoattractant protein 1 (MCP-1/MCAF),
and macrophage inflammatory protein 1 α (MIP-1α).
Data were analyzed using Bio-Plex manager software with
5PL curve fitting.
Multiparameter Surface Flow Cytometry Analysis
Unspecific antibody binding to Fc receptors from thawed
PBMC was blocked with 100% adult bovine serum
(Omega Scientific). PMBC were then stained using a panel
of fluorescein-labeled antibodies against the following T-
cell surface antigens: FITC-conjugated-UCHL1 (anti-
CD45RO), APC-CY7-conjugated-SK3 (anti-CD4), APC-
conjugated-FN50 (anti-CD69) (all from BD Biosciences,
San Jose, CA), Pacific Blue-conjugated-S4.1 (anti-CD3)
(Invitrogen, Carlsbad, CA), and ECD-conjugated-Immu-
357 (anti-HLA-DR) (Beckman Coulter). Cells were fixed
with 0.5% paraformaldehyde. Immediately before flow
cytometric analysis, 5 μL of 7-amino-actinomycin D (7-
AAD) was added to gate out dead cells. The 5 color flow
cytometry staining was acquired by a FACSAria using Flu-
orescence Minus One approach [37]. Analysis was per-
formed with FCS Express (DeNovo Software, Thornhill,
Ontario, Canada) software.
FoxP3 Intracellular Staining
PBMC were first labeled with the following surface anti-
bodies: Pacific Blue-conjugated-S4.1 (anti-CD3),
AlexaFluor467-conjugated-RPA-T4 (anti-CD4), APC-CY7-
conjugated-M-A251 (anti-CD25). Intracellular staining
for FoxP3 protein was performed following the manufac-
turer's instructions using the PE-conjugated-PCH101 anti-
FoxP3 antibody (eBioscience, San Diego, CA). Flow cyto-
metric analysis was performed as described above.
Real-Time Quantitative Polymerase Chain Reaction 
(QPCR) for FoxP3
Total RNA was extracted from thawed PBMC using RNe-
asy mini kit (Qiagen, Valencia, CA). Human FoxP3 mRNA
expression was quantified using the iScript One-Step
Quantitative reverse-transcriptase PCR kit (Bio-Rad) in an
Opticon 2 (MJ Research, Ramsey, MN), and sample con-
centrations were corrected with human 18S rRNA [38].
Amplification was conducted in a total volume of 25 μL
for 40 cycles of 15 seconds at 95°C, 30 seconds at 60°C
and 30 seconds at 72°C, with 2 beginning steps: 10 min-
utes at 50°C (to convert RNA to cDNA) and 15 seconds at
95°C (to inactivate reverse transcriptase). Samples were
run in triplicate. FoxP3 primers were forward 5'-CAA GTT
CCA CAA CAT GCG AC-3'; and reverse, 5'-ATT GAC TGT
CCG CTG CTT CT-3' [39]. 18S rRNA, primers were for-
ward 5'-GC-CGA-AGC-GTT-TAC-TTT-GA-3' and reverse
5'-TCC-ATT-ATT-CCT-AGC-TGC-GGT-ATC-3' [38].
Tumor Processing for Tetramer Assay
To generate a single-cell suspension and analysis of tumor
infiltrating lymphocytes (TIL), tumors obtained from an
outpatient excisional biopsy were decapsulated, minced
with sterile surgical blades and enzymatically digested for
1 to 2 hours with DNAse I (0.1 mg/mL, Sigma) and colla-
genase D (1 mg/mL, Boehringer Mannheim, Indianapolis,
IN) in 100 mL of AIM-V® media (Gibco-BRL). Cells were
plated in flasks in RPMI culture media and allowed to
adhere for 2 hours. At that time, nonadherent cells,
enriched for TIL, were collected and cryopreserved for
tetramer analysis.
Statistical Analysis
The previously defined 99% RCV [29] was applied to
detect statistically significant changes in values above the
lower limit of detection for the tetramer and ELISPOT
assays. Data from all assays were normalized to an arbi-
trary scale from 0 to -4 or +4 change from baseline for the
generation of heat maps for unsupervised and supervised
hierarchical clustering of results. The mean of the results
of 2 predosing samples was given a value of 0, and post-
dosing changes could be either positive or negative. For
tetramer and ELISPOT assay results, positive changes <
99% RCV were scored as 1, twice the RCV was scored as 2,
3 times the RCV as 3, and 4 was scored for any result
beyond this point. Negative changes compared with base-
line were scored with the corresponding negative values
from -1 to -4. The percentage change from baseline for
surface flow cytometry results and QPCR was calculated
for FoxP3 mRNA as described by Maker et al [40]. A value
of 1 was assigned for a positive or negative percentage
change between 0 and 50% from baseline, 2 for percent-
age changes between 51% and 100%, 3 for percentage
changes between 101% and 150%, and 4 for changes
beyond 151%. Samples were analyzed by pairwise aver-
age-linkage cluster analysis [41] using dChip software ini-
tially developed for genome-wide microarray expression
data analysis. In this analysis, data vectors typically
assigned as gene probe sets were substituted with the
aforementioned transformed tetramer, ELISPOT, flow
cytometry, and QPCR serial data points. Samples were
assigned vector columns, and assay points were assignedJournal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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vector rows. In addition, a paired t test was used to deter-
mine significant changes in pre- and postdosing levels of
the surface markers HLA-DR and CD45RO.
Results and Discussion
Patient Characteristics
Twenty-three HLA-A*0201-positive patients with surgi-
cally incurable stage IIIc or IV MART1-positive melanoma
provided a baseline blood sample for screening analysis
of circulating CD8+  T cells specific for MART126–35
epitope. Patients with a baseline value within the measur-
able range for the tetramer analysis (≥ 0.03%) were
selected. The inclusion of this criterion was based on the
goal of quantification of both positive and negative
changes in the number of circulating MART126–35-specific
T cells after treatment with tremelimumab. Patients with
baseline levels of MART126–35-specific T cells below the
assay LLD would not contribute to assessing a potential
decrease in circulating T cells specific for this antigen upon
treatment with CTLA4 blocking antibodies [29], a possi-
bility that has not been excluded in prior studies
[8,9,14,19,40,42]. Fifteen patients were enrolled and 12
received 2 or more monthly doses of tremelimumab; 2
patients experienced rapid tumor progression before the
second scheduled dose, and 1 patient never received the
first dose due to rapid deterioration of performance status.
The 12 patients who received at least 2 doses of tremeli-
mumab were considered evaluable for immune-monitor-
ing assays, and their characteristics are summarized in
Table 1.
Toxicities
None of these patients developed a grade 4 treatment-
related toxicity; however, 5 patients experienced treat-
ment-related grade 3 toxicities. Two (1105A and 1108)
developed marked increase in transaminases after 11 and
5 doses, consistent with hepatitis (Table 1). Acute viral
hepatitis was ruled out in both cases. In both cases this
was a reason for study discontinuation. Although neither
patient received corticosteroids, both fully recovered
within 2 months. One of these patients underwent 5 daily
therapeutic plasma exchange procedures with efficient
clearance of detectable levels of circulating tremelimu-
mab. Two patients (1106 and 1114) developed grade 3
diarrhea after 4 and 2 doses. One underwent colonoscopy
and biopsy, which demonstrated histologically proven
colitis with lymphomonocytic infiltrates predominantly
by CD4+ T helper cells and CD68+ macrophages (Figure
1). A final patient (1109) developed a generalized rash,
which was described as leukocytoclastic vasculitis at
biopsy. Clinically significant grade 2 toxicities included 2
cases of panhypopituitarism suggestive of hypophysitis,
patient 1108 after 5 doses and patient 1113 after 22 doses
of tremelimumab. This later patient also developed ante-
rior uveitis after 21 doses that rapidly improved following
treatment with corticosteroid-containing eye drops.
Clinical Responses
One patient (1108) achieved a complete response of 2
nodal metastases that were proven to be melanoma at
baseline by fine needle aspiration. This response is ongo-
ing 39+ months later. One patient (1111) had a major
partial response of bulky in-transit metastasis, and
remains relapse-free at 34+ months (Figure 2A and 2B). A
third patient (1113) did not qualify as a responder by
RECIST criteria but was determined to have unequivocal
evidence of clinical benefit. A [18F]fluorodeoxy-glucose
(FDG) positron-emission tomography (PET)-positive 4-
cm psoas muscle mass became PET negative after 9 doses.
Upon surgical resection, pathological analysis showed a
90% regression of melanoma with no disease progression
at 33+ months. This patient is listed as having a patholog-
ical partial response. Only 1 of 5 patients with grade 3 tox-
icity had an objective clinical response.
MHC Tetramer Assay
T cells from treated patients were screened to determine
whether responses to tumor-specific antigens developed
as a result of treatment with tremelimumab. A mean of 2
baseline and 7 follow-up (range, 5 to 9) blood draws per
patient were tested. Samples were analyzed by flow
cytometry for negative tetramer-specific MART126–35-spe-
cific CD8+ T cells. Percentages of negative tetramer-specific
and MART126–35-specific CD8+ T cells at each time point
indicated increases beyond the 99% RCV in 4 patients on
more than 1 occasion (Figure 3). However, these were
spikes of peripheral appearance of melanoma antigen-
specific T cells at isolated time points, as opposed to per-
sistent elevations in several blood draws taken after dos-
ing. Patient 1111, who had an objective clinical response
to therapy, underwent biopsy of a responding lesion.
MHC tetramer analysis of nonadherent cells from this
lesion demonstrated a 6-fold enrichment of gp100209–217-
specific CD8+ T cells among total CD8+ T cells compared
with peripheral blood (Figure 2C and 2D).
To efficiently present all of the data describing positive or
negative changes across 12 patients, multiple time points,
and the different test epitopes (a total of 719 assay
results), the data were converted to a -4 to +4 scale based
on the 99% RCV (as described in the Materials and Meth-
ods and Table 2) and color coded in shades of blue for
negative changes and red for positive changes. These data
were compiled in a heat map similar to the ones used to
analyze data from gene expression profiling (Figure 4). As
described for MART126–35-specific T cells, no definite
trend was observed for changes over time in the propor-
tion of CD8+ T cells reacting to any melanoma-(gp100209–
217, tyrosinase368–376) or infectious disease-(EBVJournal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
Page 6 of 14
(page number not for citation purposes)
BMLF1259–267, CMVpp65495–503) specific antigen in any
patient.
IFN-γ ELISPOT Assay
The heat map in Figure 4 also presents all the data gener-
ated by ELISPOT assay enumerating cells producing IFN-γ
after short ex vivo peptide stimulation. Results are color
coded following the -4 to +4 scale range with negative and
positive changes defined by the 99% RCV compared with
the results from the 2 baseline samples (Table 2). The data
summarize replicate results from a mean of 9 (range, 6 to
11) time points analyzed from the 12 study patients test-
ing reactivity to the negative control and test antigens for
a total of 1,694 sample results. As with the tetramer assay,
there was no evidence of a consistent change over time in
the assay results for any of the tested epitopes.
Multiplex Cytokine Production Upon Antigen Exposure
The possibility that IFN-γ may not be the most significant
cytokine to define the functional status of antigen-specific
T cells after CTLA4 blockade was explored. Therefore, we
set up cocultures of 2 × 105 PBMC and 2 × 104 K562/
A*0201 cells pulsed with either negative, MART126–35,
tyrosinase368–376,  and gp100209–217  peptides in parallel
Table 1: Patient characteristics, toxicities, and response to therapy
Patient code Age Sex Stage Disease 
sites
Prior therapy Tremelimumab 
doses, no.
Treatment-related 
toxicity, G2/G3
Best response
1103 80 M IVc Liver 2 Diarrhea G2 PD
Lung
1104 63 M IVb LN Temozolomide, 
thalidomide, IL-2
2P D
Lung
Liver
Adrenal
Kidney
1105A 61 M IVc LN Cisplatin, vinblastine, 
temozolomide, IL-2, IFN, 
lenalidomide, MART1/DC
11 Hepatitis G3 Acne 
Rosacea G2
SD × 11 mos
Lung
Stomach
1105P 55 F IVc LN Cisplatin, vinblastine, 
dacarbazine, paclitaxel, 
gefitinib, BCG, IL-2, IFN
4P D
Lung
Liver
1106 52 F IVc LN Cisplatin, vinblastine, 
dacarbazine
4 Diarrhea G3 Rash G2 PD
Lung
Liver
1107 57 M IVc LN Heat shock 2 PD
Liver Protein
1108 55 F IIIc SC GM-CSF 5 Hepatitis G3 Hypophysitis 
G2
CR × 39+ mo.
LN
1109 54 M IVa LN ILX 651 3 Leuko-cytoclastic 
vasculitis G3
PD
1110 34 M IVa SC IL-2 3 PD
LN
1111 90 M IIIc Skin BCG, 8 Diarrhea G2 PR × 34+ mo.
LN AMG 706
1113 63 M IVa LN IFN 22 Hypophysitis G2 Elevated 
trans-aminases G2 
Asthenia G2 Arthralgia 
G2 Grover's G2 Uveitis 
G2
pPR × 33+ mo.
1114 61 M IVa LN IFN, temozolomide 2 Colitis G3 SD × 8 mo.
No. = Number; G = Grade; M = Male; PD = Progressive disease; LN = Lymph node; IL-2 = Interleukin-2; SD = Stable disease; mo.= Months; IFN = 
Interferon; MART1 = Melanoma-associated antigen recognized by T cells; DC = Dendritic cells; F = Female; BCG = Bacillus Calmette-Guérin; SC = 
Subcutaneous; GM-CSF = Granulocyte-macrophage colony-stimulating factor; CR = Complete response; PR = Partial response; pPR = Pathological 
partial response.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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with the ELISPOT assays of patients 1108, a responder,
and 1110, a nonresponder. Twenty hours later superna-
tants were collected and analyzed with a bead-based mul-
tiplex assay of 17 cytokines (background [PBMC plus
K562/A*0201] was subtracted from all samples). The
PBMC cytokine profile from patient 1110 was under the
assay limit of detection except for baseline IL-8, MCP-1,
and MIP-1β. In contrast, cell supernatant from patient
1108 showed that IL-6, IL-8, G-CSF, MCP-1, and MIP-1β
increased after dose 1 (week 2) and dose 2 (week 3) only.
IFN-γ, TNF-α, IL-7, and IL-13 demonstrated a small
increase after dose 2 (week 3). The cytokines IL-2, IL-4, IL-
5, IL-10, IL-17, GM-CSF, and IL-12(p70) were not
detected in supernatants of this patient (data not shown).
From this preliminary analysis, we concluded that multi-
cytokine analysis in these 2 representative patients was
unlikely to provide additional information beyond the
information obtained by the standardized IFN-γ ELISPOT.
Analysis of T-Cell Activation and Memory Markers
Based on the emerging results suggesting that there was no
consistent change in the number of circulating CD8+ T
cells specific for melanoma or infectious disease antigens
analyzed by either biochemical (tetramer) or functional
(ELISPOT and multicytokine) assays, we sought evidence
of T-cell activation regardless of antigen specificity. Cell
surface expression of the activation-induced T-cell marker
HLA-DR (MHC class II molecule) and the T-cell memory
marker CD45RO have been reported to be increased after
administering CTLA4-blocking monoclonal antibodies
[8,9,14,19,40]. Ten patients had at least 1 baseline and 1
postdosing aliquot of PBMC available for this analysis, for
a total of 81 analyzed samples. There was no overall sig-
nificant increase in the expression of these 2 surface mark-
ers on either CD4+ and CD8+ T-cell subsets comparing pre-
and postdosing samples, although HLA-DR and CD45RO
were significantly increased on CD4+ cells after the first
dose (paired t  test P  = .02 and .01, respectively), and
CD45RO was significantly increased on CD8+ cells after
cycles 1 and 2 (paired t test P = .009 and .04, respectively).
Results were then converted to percentage change from
baseline as described by Maker et al [40] and assigned a
score from -4 to +4 (Table 2) to allow compiling of data
in the heat map (Figure 4).
Analysis of FoxP3 mRNA and Intracellular Protein
An alternative possibility was that CTLA4-blocking anti-
bodies affected CTLA4-positive Treg. Other groups have
Grade 3 colitis with tremelimumab Figure 1
Grade 3 colitis with tremelimumab. High magnification images of a biopsy of the colon in patient 1114. Sections from paraffin-
embedded tissue were stained by hematoxylin-eosin (H&E) and CD3, CD4, CD8, CD68, and granzyme B by immunohisto-
chemistry using commercially available antibodies.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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explored this possibility with divergent results [14,19,40].
In 8 patients (including the 3 patients with clinical bene-
fit), aliquots of at least 1 baseline and 1 follow-up PBMC
sample were available for analysis using QPCR to quanti-
tate FoxP3 mRNA transcripts. We failed to detect a statis-
tically significant change (either positive or negative)
between pre- and postdosing results. Results from the 56
total tested samples were converted to the same scale used
for the flow cytometry data (Table 2) and compiled in the
heat map (Figure 4).
There were not enough cells derived from the 40 mL
peripheral blood draws to perform functional assays of
Treg-mediated suppression. In a further attempt to test a
possible effect of tremelimumab on circulating Treg,
expression of the intracellular FoxP3 protein in cells with
the CD3+CD4+CD25high phenotype was analyzed by flow
cytometry. This included at least 1 baseline and 1 postdos-
ing representative sample taken from 2 responders (1108
and 1111) and 3 nonresponders (1103, 1105A, and
1110), for a total of 19 analyzed samples. Data were again
converted to percent change from baseline, scored with
values between -4 and +4, and compared with results
from FoxP3 mRNA analysis at the same time points. There
was good concordance between the results of both assays
at 9 time points, whereas at the other 10 time points both
assays diverged at values ≥ 2 or ≤ -2 (data not shown).
These discrepancies underscore the difficulty in efficiently
quantifying Treg using currently available approaches.
Clinical response to tremelimumab Figure 2
Clinical response to tremelimumab. (A) Baseline picture of patient 1111 intransit metastases, which were progressing after 
experimental therapy with an antiangiogenic agent. (B) Follow-up picture 5 months after initial dosing while receiving monthly 
tremelimumab at 10 mg/kg. (C) Dot plot of MHC tetramer analysis taken from peripheral blood at cycle 3. (D) Dot plot of 
MHC tetramer analysis of tumor infiltrating lymphocytes from a tumor biopsy of a regressing melanoma lesion at cycle 3. MHC 
= Major histocompatibility complex.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
Page 9 of 14
(page number not for citation purposes)
Unsupervised Hierarchical Relations Between Immune 
Monitoring and Clinical Results
The data compiled in the heat map presented in Figure 4
contain all available results of postdosing values com-
pared with the mean of the 2 baseline assay results (with
a score of 0). Because the data were converted to a normal-
ized scale of -4 to +4 based on what were determined to
be biologically significant changes over baseline, a hierar-
Major histocompatibility complex tetramer analysis in patients receiving tremelimumab Figure 3
Major histocompatibility complex tetramer analysis in patients receiving tremelimumab. Bar graphs represent percentages of 
CD8+ T cells specific for (A) negative control epitope and (B) MART126–35 in samples from all patients and available time points 
in the tetramer analyses. MART1 = Melanoma-associated antigen recognized by T cells; EOS = End of study.
Table 2: Percent change from mean baseline normalized to a scale of ± 4
Assay Epitope 1 2 3 4
MHC tetramer EBV BMLF1259–267 ≥85.89 ≥171.78 ≥257.67 ≥343.56
CMVpp65495–503 ≥69.89 ≥138.58 ≥207.87 ≥277.16
MART126–35 ≥107.29 ≥214.58 ≥321.87 ≥429.16
Tyrosinase368–376 ≥107.29 ≥214.58 ≥321.87 ≥429.16
gp100209–217 ≥107.29 ≥214.58 ≥321.87 ≥429.16
IFN-γ ELISPOT EBV BMLF1259–267 ≥246.85 ≥493.7 ≥740.55 ≥987.4
CMVpp65495–503 ≥192.4 ≥384.8 ≥577.2 ≥769.6
MART126–35 ≥264.1 ≥528.2 ≥792.3 ≥1,056.4
Tyrosinase368–376 ≥264.1 ≥528.2 ≥792.3 ≥1,056.4
gp100209–217 ≥264.1 ≥528.2 ≥792.3 ≥1,056.4
HLA-DR 0 – 50 51 – 100 101 – 150 150 – 200+
CD45RO 0 – 50 51 – 100 101 – 150 150 – 200+
QPCR 0 – 50 51 – 100 101 – 150 150 – 200+
MHC = Major histocompatibility complex; EBV = Epstein-Barr virus; CMV = Cytomegalovirus; MART1 = Melanoma-associated antigen recognized 
by T cells; IFN-γ = Interferon gamma; ELISPOT = Enzyme-linked immunospot; HLA = Human leukocyte antigen; QPCR = Quantitative polymerase 
chain reaction.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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chical unsupervised clustering analysis could be per-
formed to process all these data in a collective but
exploratory approach. This analysis segregated the study
patients randomly, with no clustering of patients by clini-
cal response (Figure 4). Unsupervised hierarchical cluster-
ing also did not separate patients with grade 2/3
treatment-related toxicities from patients without treat-
ment-related toxicity. We then conducted more limited
unsupervised clustering including the results of the
tetramer, IFN-γ ELISPOT, or FoxP3 QPCR data alone.
Again, patients clustered randomly. However, when we
conducted the unsupervised clustering for HLA-DR and
CD45RO markers, the 3 clinical responders segregated
along with several nonresponders with evidence of
inflammatory toxicity (1105A with grade 3 hepatitis,
1106 with grade 3 diarrhea, 1109 with grade 3 leukocyto-
clastic vasculitis). This segregation was statistically signifi-
cant (P = .05; Figure 5A) and suggests that patients with an
objective tumor response and/or toxicity after administra-
tion of tremelimumab have a more active immune
response detectable in peripheral blood.
Supervised Hierarchical Relation of Immunologic 
Monitoring Data According to Clinical Responses
The data set was then examined to explore which assay
results better segregated the 3 clinical responders from
nonresponders (Figure 5B). Increase in CD45RO on CD4+
cells after 3 doses and increase in HLA-DR on CD8+ cells
after 2 doses significantly differentiated responders from
nonresponders (2-fold cutoff difference, P = .03). These
data strengthen the correlation between nonantigen-spe-
cific markers of immune activation on T cells and antitu-
mor activity.
Conclusion
Several reports have described immune monitoring in
peripheral blood of patients receiving CTLA4-blocking
monoclonal antibodies [8,9,14,19,40,42]. These prior
studies did not collect repeated samples allowing time-
course analysis of circulating antigen-specific T cells for
melanoma and infectious-disease antigens. Analysis of a
single time point may miss transient changes (either pos-
itive or negative) in circulating cells, or may result in
biased results given our prior observation of occasional
peaks of circulating T cells at isolated time points [42].
Therefore, we decided to collect a time course of blood
samples from consenting patients treated with a fixed
dose and schedule of the CTLA4-blocking antibody treme-
limumab.
We selected a cohort of HLA-A*0201-positive patients
with MART1-positive melanoma who had received at least
2 doses of tremelimumab and had a measurable level of
circulating MART126–35-specific T cells to allow analysis of
the primary study endpoint. We acknowledge that this is 
Unsupervised hierarchical clustering of clinical parameters  and tetramer, ELISPOT, HLA-DR, CD45RO, and FoxP3  QPCR for all patients and available time points Figure 4
Unsupervised hierarchical clustering of clinical parameters and tetramer, ELISPOT, 
HLA-DR, CD45RO, and FoxP3 QPCR for all patients and available time points. Each 
column represents results for 1 patient. The first 5 rows describe clinical features of 
patients, including response to therapy (0 = No response; 1 = Response), site (U = 
University of California, Los Angeles; M = MD Anderson), sex (M = Male; F = 
Female), stage (3 = IIIc; 4 = IV), age, and metastasis (0 = Lung; 1 = Nodes; 2 = Liver; 
3 = Subcutaneous; 4 = Skin; 5 = Stomach; 6 = Adrenal; 7 = Kidney). The rest of the 
rows represent test results at different time points after dosing. White represents 
no change (0 value) or absence of data (which is not included in the clustering algo-
rithm). Red and shades of red represent positive changes on a scale of 1 to 4. Blue 
and shades of blue represent negative changes on a scale of 1 to 4. Data are normal-
ized to a -4 to +4 scale as described in Table 2. ELISPOT = Enzyme-linked immunos-
pot; HLA = Human leukocyte antigen; QPCR = Quantitative polymerase chain 
reaction; EBV = Epstein-Barr virus; MART1 = Melanoma-associated antigen recog-
nized by T cells; EOS = End of study.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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Clustering of clinical parameters and HLA-DR and CD45RO surface staining Figure 5
Clustering of clinical parameters and HLA-DR and CD45RO surface staining. (A) Unsupervised clustering of the results from surface staining of CD4+ and 
CD8+ cells for the T-cell activation marker HLA-DR and the T-cell memory marker CD45RO. (B) Supervised clustering of immune response parameters 
according to response to therapy. Each column represents results for 1 patient. The first 5 rows describe clinical features of patients, including response to 
therapy (0 = No response; 1 = Response), site (U = University of California, Los Angeles; M = MD Anderson), sex (M = Male; F = Female), stage (3 = IIIc; 
4 = IV), age, and metastasis (0 = Lung; 1 = Nodes; 2 = Liver; 3 = Subcutaneous; 4 = Skin; 5 = Stomach; 6 = Adrenal; 7 = Kidney). The rest of the rows rep-
resent test results at different time points after dosing. White represents no change (0 value) or absence of data (which is not included in the clustering 
algorithm). Red and shades of red represent positive changes on a scale of 1 to 4. Blue and shades of blue represent negative changes on a scale of 1 to 4. 
Data are normalized to a -4 to +4 scale as described in Table 2. All test results were included in the analysis, and the graph represents the results that best 
discriminate clinical responders (1108, 1111, 1113) from nonresponders, setting a 1.2-fold difference as the cutoff. Each column and row is presented as 
described in Figure 4, and the data are normalized to a -4 to +4 scale as described in Table 2. HLA = Human leukocyte antigen; EOS = End of study; QPCR 
= Quantitative polymerase chain reaction.Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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a selected population of patients, and this analysis was
aimed at testing both positive and negative changes in
antigen-specific T cells in peripheral blood. Contrary to
what has been reported by others [9,14], we did not
observe a significant correlation between the develop-
ment of toxicities that may have an autoimmune mecha-
nism of action with clinical responses. A limitation of our
analysis is the small number of patients, resulting in lower
power to detect statistically significant correlations. How-
ever, we did note that certain toxicities, like hepatitis and
anterior uveitis, may be more common with repeated dos-
ing, something that has been previously described for
hypophysitis [43]. Two unique skin toxicities with treme-
limumab were noted in our patients, leukocytoclastic vas-
culitis and Grover's disease of the skin.
Our data confirm observations by others [8,9,19,40] that
administration of CTLA4-blocking antibodies to patients
with melanoma does not result in the sustained expan-
sion of circulating melanoma antigen-specific CD8+ T
cells. It further rules out that this intervention decreases
the number of circulating melanoma antigen-specific T
cells. However, the observed marked enrichment of
gp100209–217-specific CD8+ T cells in regressing tumor tis-
sue compared with peripheral blood in 1 patient suggests
that sampling of circulating antigen-specific T cells might
miss overall melanoma antigen-specific T-cell expansion
in the tumor. This may be particularly relevant for studies
without time-course sampling. The occasional peaks of
increased numbers of melanoma-circulating antigen-spe-
cific T cells detected in several patients may reflect peaks
of T-cell expansion at different time points that may not
persist because the cells accumulate in tumors. We rea-
soned that this possibility could be better analyzed when
the data were studied in an unbiased manner using unsu-
pervised clustering analysis of data presented in heat
maps. However, even with this analysis, we were unable
to correlate the activation or expansion of circulating
melanoma antigen-specific CD8+ T cells with clinical ben-
efit to CTLA4 blockade. It is certainly possible that the 3
melanoma antigens studied may not be relevant for
CTLA4 blockade-induced melanoma regressions. How-
ever, these 3 antigen epitopes have been repeatedly recog-
nized as HLA-A*0201 immunodominant peptides in
patients with immunotherapy-induced tumor regressions
[44].
The constitutive expression of CTLA4 on Treg has raised
the possibility that administration of anti-CTLA4 antibod-
ies may deplete or modulate the function of these profes-
sional immune suppressive cells [45,46]. However,
neither ipilimumab nor tremelimumab were selected as
depleting antibodies for CTLA4-positive cells. In fact, both
antibodies were selected as blocking antibodies to CTLA4
intended to activate cells expressing their target but not
kill them. Furthermore, tremelimumab is an IgG2 anti-
body, an immunoglobulin subtype unlikely to fix com-
plement or induce antibody-mediated cellular
cytotoxicity [47]. Treg are difficult to study at the cellular
level because they have a surface phenotype that is indis-
tinguishable from chronically activated T helper cells.
They can be detected by the intracellular expression of the
Treg-specific transcription factor FoxP3 [48,49]. FoxP3
mRNA transcripts in a population of PBMC can be quan-
titated by QPCR; however, this technique does not allow
efficient enumeration of Treg at the cellular level. Intracel-
lular FoxP3 protein staining can be achieved by multi-
color flow cytometry after cell permeabilization, but it is
currently unclear how these 2 techniques compare and the
bias of each analytical methodology. The gold standard
assay for detecting Treg is the determination of their func-
tional ability to inhibit the proliferation of clonally
expanded T cells [20]. However, insufficient quantities of
blood were collected to perform this type of analysis.
Therefore, our findings of no evidence of Treg depletion in
peripheral blood samples by FoxP3 QPCR and intracellu-
lar staining should be interpreted with caution. Paired
FoxP3 mRNA quantitation and Treg functional analysis
have been reported by Maker et al [40]. These investiga-
tors concluded that administration of the CTLA4-blocking
antibody ipilimumab to patients with melanoma neither
depleted Treg nor downregulated their functional
immune suppressive activity. Our data and the data
reported by Maker et al are in contrast to data presented
by Reuben et al [14] who suggested that Treg defined by
flow cytometry may be preferentially depleted in patients
with an objective response to the CTLA4 blocking anti-
body tremelimumab, and O'Mahony et al [19] who sug-
gested that Treg defined by FoxP3 QPCR may transiently
decrease in peripheral circulation 3 days after dosing and
recover 4 weeks later.
We analyzed tumor and infectious disease antigen-spe-
cific CD8+  T-cell immune monitoring, FoxP3 mRNA
quantitation, and T-cell activation/memory marker sur-
face staining concurrently to detect trends relating to clin-
ical parameters. We considered applying a stepwise
regression analysis to search for variables that are signifi-
cantly associated with clinical response. However, our
sample size was too small for such an analysis, especially
considering that this cohort included only 3 clinical
responders. Therefore, to accomplish the goal of generat-
ing an overall evaluation of immune monitoring data, we
turned to cluster analysis as a means to look at the data in
an exploratory fashion. Markers of T-cell activation (HLA-
DR) and memory phenotype (CD45RO) after dosing with
tremelimumab segregated the 3 patients with clinical ben-
efit together with 4 patients with inflammatory toxicity.
Therefore, we conclude that tremelimumab does not
increase the number or function of antigen-specific CD8+Journal of Translational Medicine 2008, 6:22 http://www.translational-medicine.com/content/6/1/22
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T cells in peripheral blood nor decrease FoxP3 transcripts
but appears to generally enhance T-cell activation and dif-
ferentiation. Detection of T-cell activation and memory
markers may be useful as readout of this antibody's ability
to activate the immune system, which may lead to phar-
macodynamic effects consistent with its observed antitu-
mor activity. Sampling of T cells in tumors may provide
additional information, and future studies should include
immune monitoring in tumor tissues.
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